An investigation on behalf of investors of Ra Medical Systems, Inc. (NYSE: RMED) shares over potential securities laws violations by Ra Medical Systems, Inc. and certain of its directors and officers in connection with certain financial statements was announced.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Ra Medical Systems, Inc. (NYSE: RMED) concerning whether a series of statements by Ra Medical Systems, Inc. regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

Carlsbad, CA based Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. In September 2018, Ra Medical completed its initial public offering (IPO), issuing approximately 4.5 million shares of common stock priced at $17.00 per share. On March 14, 2019, Ra Medical Systems, Inc reported its fourth quarter and full year financial results. Ra Medical Systems, Inc. reported that its annual Total Revenue rose from $5.87 million in 2017 to $6.25 million in 2018 and that its Net Loss increased from $17.76 million in 2017 to $30.83 million in 2018.

Shares of Ra Medical Systems, Inc. (NYSE: RMED) declined from $10.19 per share in early 2019 to as low as $3.39 per share on March 29, 2019.